Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
about
Optimal management of seizures associated with tuberous sclerosis complex: current and emerging optionsRapamycin and rapalogs for tuberous sclerosis complexNew advances in targeted gastric cancer treatmentThe mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trialsRapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysisThe search for circulating epilepsy biomarkersGene-environment interactions in severe intraventricular hemorrhage of preterm neonatesPI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancerLymphangioleiomyomatosis: differential diagnosis and optimal managementProspects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyTargeting translation initiation in breast cancerInflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.Stochastic model of Tsc1 lesions in mouse brainTherapeutic targeting of cancers with loss of PTEN function.Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.Everolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateTargeted Therapies for Brain Metastases from Breast CancerOptimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic reviewIs mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapyMolecular Connections between Cancer Cell Metabolism and the Tumor MicroenvironmentTranslational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Effect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young RatsAttributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions.Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.Chordoma Occurs in Young Children With Tuberous Sclerosis.Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.Successful treatment of Kaposiform hemangioendothelioma with everolimus.Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report.Treatment-related mortality with everolimus in cancer patients.Persistent Hepatitis E Infection in a Patient with Tuberous Sclerosis Complex Treated with Everolimus: A Case Report.Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.The genomic landscape of tuberous sclerosis complexPediatric low-grade gliomas: how modern biology reshapes the clinical field.Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complexSerum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trialCongenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex.
P2860
Q22305852-D2FAC9A6-0ED4-42AC-A1F1-D82B9CD98C37Q26471128-FF211AEE-C2CD-4AD2-A68F-AA513E9E9337Q26738548-53128C50-46BB-4998-AEB9-43D91F5FE317Q26751155-C6CE7F27-624E-4B7A-94A6-03D52171F978Q26799757-6BEBD1B2-1A58-4FAD-BF18-96D338466545Q26851663-29E87DE6-70AC-41C5-9413-9707E0FE172CQ26996782-141BF4D4-359A-4211-A40C-A2994C32AFBFQ27006181-1EA988CA-B818-4636-B1A3-3151EF8057B7Q27022412-1407B9D9-FE68-4DAD-B5A4-6CED64B662EDQ27025344-8E062AB8-DE92-4232-B339-DD265AA5C884Q27027284-CDCE7940-7AE5-4748-BAD0-AB33D0BD3D86Q27308042-1312ABF0-C2F9-4892-A132-679CA01971EDQ27319406-1357B02E-F66C-4456-8BD5-22D1826C3D40Q27852764-564C38B1-1DB8-4890-AEE3-E6A8CFB6CB24Q27853117-1588C0DE-7423-4A7D-A884-338F0663F7A3Q28067598-C2F06638-C734-470A-A55F-72CFEE0C83C8Q28068154-1FE02919-5B26-4191-9E9C-06E3F4CA8EF3Q28071646-3BF1C35B-8761-4B9C-B493-5CB5BCAC396BQ28075954-81266B22-72F0-4C4C-9C6F-3FD6FB0B428EQ28078328-5002C8A6-40A3-48FB-A5F9-25074363D544Q28081657-2D64A7F9-1FB1-46D8-BD6B-075D6B20E7D8Q28394524-E6EC1418-A2C3-4023-B87A-92D33BEE654EQ28547057-1D07E280-6294-44C0-9302-3CDAF770B03CQ30243969-4305342D-1C77-47DF-8ED3-90E6F5B58AACQ30415483-818D9BA7-217C-4269-94B2-486F275C53D4Q30747071-B83AA0F5-8E28-4746-A6AE-EB7A838CDCDDQ31140724-F51BE3A8-0A19-4DC6-A6C8-A05B7DEECF6AQ33276501-97E14B68-6837-422E-B685-56F2EB632A27Q33411585-96503551-322D-4199-A6F0-F129F361EFC3Q33418149-B9ACAD56-8248-4434-BA34-0347A096BF0AQ33694246-018331D2-903D-4B62-AF10-8719E04CC76AQ33699582-5B6DD7BF-251E-4F83-BB88-E59AF2EE9DA3Q33732518-B3DFEC39-FAB8-470B-9EB1-CBCBDC170F95Q33757948-C1A0ACB9-85FA-4BFD-9681-36F1F1CC9139Q33823243-37CD3804-1767-4EC8-9794-5401D1DED92AQ33826893-905A04D4-E3D6-4A83-A530-BF73A0C0483BQ33847771-6A2F0E5B-D278-4182-8593-5F27355811DFQ34375115-CEE34CFD-9B87-4345-A87D-19648048C86BQ34380247-A7AC489B-084F-4589-9B29-2F8AEBFE9EC3Q34468812-C70CC844-C2D7-4D6C-8FE0-96B747FF2014
P2860
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy and safety of everoli ...... cebo-controlled phase 3 trial.
@en
type
label
Efficacy and safety of everoli ...... cebo-controlled phase 3 trial.
@en
prefLabel
Efficacy and safety of everoli ...... cebo-controlled phase 3 trial.
@en
P2093
P921
P1433
P1476
Efficacy and safety of everoli ...... acebo-controlled phase 3 trial
@en
P2093
David Lebwohl
David Neal Franz
E Martina Bebin
Elizabeth A Thiele
Gaurav Shah
Helene Cauwel
J Robert Flamini
James P Ford
Joyce Y Wu
Michael Frost
P304
P356
10.1016/S0140-6736(12)61134-9
P407
P577
2012-11-14T00:00:00Z